US Patent Issued to University of Washington on Jan. 28 for "Engineering the RRM2 subunit of ribonucleotide reductase to resist degradation" (Washington Inventors)

ALEXANDRIA, Va., Jan. 29 -- United States Patent no. 12,208,133, issued on Jan. 28, was assigned to University of Washington (Seattle).

"Engineering the RRM2 subunit of ribonucleotide reductase to resist degradation" was invented by Michael Regnier (Seattle), Charles E. Murry (Seattle) and Xuan Guan (Seattle).

According to the abstract* released by the U.S. Patent & Trademark Office: "Provided herein are isolated nucleic acids that encode a stable form of Rrm2 for the use of increasing the intracellular Rrm2 protein levels and cytosolic 2-deoxy-ATP (dATP) levels. Further provided herein are methods for treating a cardiac disease or disorder, e.g., myocardial infarction or myocardial ischemia, by administering the isolated nucleic acids, a...